Drug Profile
Delmitide
Alternative Names: Allotrap 1258; Rationally Designed Peptide 58; RDP 1258; RDP 58Latest Information Update: 31 Mar 2022
Price :
$50
*
At a glance
- Originator Genzyme Corporation
- Developer Synt:em
- Class Anti-inflammatories; Peptides
- Mechanism of Action Cytokine inhibitors; Immunosuppressants; Tumour necrosis factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Crohn's disease; Ulcerative colitis
- Discontinued Atopic dermatitis; Barrett's oesophagus; Chemotherapy-induced damage; Diarrhoea; Heart transplant rejection; HIV infections; Interstitial cystitis; Multiple sclerosis; Psoriasis; Pulmonary fibrosis; Respiratory tract disorders; Uveitis
Most Recent Events
- 26 May 2010 No development reported - Phase-I for Crohn's disease in USA (PO)
- 26 May 2010 No development reported - Phase-I for Ulcerative colitis in USA (PO)
- 26 May 2010 No development reported - Phase-II for Crohn's disease in Europe (PO)